

## AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 1, line 6, as follows:

The present invention relates to a pharmaceutical composition containing as an active ingredient one or more HMG-CoA reductase inhibitor(s) for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); [[and]] or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, and,

Please amend the paragraph beginning on page 1, line 21, as follows:

a method comprising administration of an effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); [[and]] or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

Please amend the paragraph beginning on page 4, line 10, as follows:

The inventors of the present invention found that an HMG-CoA reductase inhibitor has superior glucose uptake enhancing action on warm-blooded animal cells, and is useful as a pharmaceutical composition for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); [[and]] or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, thereby leading to completion of the present invention.

Please amend the paragraph beginning on page 4, line 27, as follows:

The present invention provides a pharmaceutical composition comprising as an active ingredient one or more HMG-CoA reductase inhibitor(s) for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); [[and]] or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome, and,

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

Please amend the paragraph beginning on page 5, line 11, as follows:

a method comprising administration of an effective amount of one or more HMG-CoA reductase inhibitor(s) to a warm-blooded animal for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); [[and]] or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome.

Please amend the paragraph beginning on page 5, line 32, as follows:

(3) a pharmaceutical composition as (1) or (2), wherein the HMG-CoA reductase inhibitor is a ~~medicament~~ selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin;

Please amend the paragraph beginning on page 7, line 13, as follows:

(11) a pharmaceutical composition as (9) or (10), wherein the water-soluble HMG-CoA reductase inhibitor is a ~~medicament~~ selected from the group consisting of pravastatin and rosuvastatin;

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

Please amend the paragraph beginning on page 7, line 29, as follows:

(15) a method as (13) or (14), wherein the HMG-CoA reductase inhibitor is ~~a medicament~~ selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, cerivastatin, atorvastatin, pitavastatin and rosuvastatin;

Please amend the paragraph beginning on page 8, line 4, as follows:

(17) a method as (13) or (14), wherein the HMG-CoA reductase inhibitor is ~~a medicament~~ selected from the group consisting of pravastatin and rosuvastatin;

Please amend the paragraph beginning on page 9, line 12, as follows:

(23) a method as (21) or (22), wherein the water-soluble HMG-CoA reductase inhibitor is a ~~medicament~~ selected from the group consisting of pravastatin and rosuvastatin;

Please amend the paragraph beginning on page 17, line 29, as follows:

Since the HMG-CoA reductase inhibitor(s) serving as an active ingredient of the present invention has superior glucose uptake enhancing action in the presence or absence of insulin (preferably in the presence of insulin) in warm-blooded animal cells (preferably warm-blooded animal adipocytes), it is useful as a pharmaceutical composition for enhancement of glucose uptake into warm-blooded animal cells (preferably warm-blooded animal adipocytes); enhancement of glucose uptake into warm-blooded animal cells (preferably warm-blooded animal adipocytes) in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); ~~[[and]]~~ or treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome,

Please amend the paragraph beginning on page 18, line 16, as follows:

preferably for enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome; [[and]] or treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome,

Please amend the paragraph beginning on page 18, line 27, as follows:

more preferably for enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus caused by insulin resistance syndrome; [[and]] or treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome,

Please amend the paragraph beginning on page 19, line 3, as follows:

and even more preferably for enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes caused by insulin resistance syndrome; [[and]] or treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>LLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

Please amend the paragraph beginning on page 25, line 15, as follows:

From the aforementioned results, an HMG-CoA reductase inhibitor serving as an active ingredient of the present invention was determined to have superior action of enhancing glucose uptake into warm-blooded animal cells, and be useful as a pharmaceutical composition for enhancement of glucose uptake into warm-blooded animal cells; enhancement of glucose uptake into warm-blooded animal cells in the presence of insulin; treatment of diabetes, hyperglycemia, glucose intolerance or gestational diabetes mellitus; treatment or prevention of diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease); or, treatment or prevention of diabetes, hyperglycemia, glucose intolerance, gestational diabetes mellitus or diabetes complications (including retinopathy, nephropathy, neuropathy, cataract and coronary artery disease) caused by insulin resistance syndrome.

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>LLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100